Sign In
Section Navigation
Common TitleHPTN 084 (LIFE Study)
Official Title A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Phase Phase III
ClinicalTrials.gov NCT03164564
Treatments
Cabotegravir

Cabotegravir

Tradename:ApretudeOther Names:CAB-LA, Injectable cabotegravirClass:Integrase Strand Transfer Inhibitors (INSTI)
Categories PREP
Funding
IndustryViiV Healthcare
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID and Bill and Melinda Gates Foundation
References
  • Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779–89.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.